Greg Mullen, Chief Executive Officer of Theragnostics, said:
"Theragnostics' strategy is to develop novel diagnostic imaging agents and targeted radionuclide therapies to improve treatment of a range of cancers. This agreement with AstraZeneca strengthens our IP estate and enables us to accelerate the development of our rPARPi therapy and diagnostic portfolio which has the potential to offer new and expanded treatment options to patients in a number of cancers."
Ad Statistics
Times Displayed: 19090
Times Visited: 362 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
The agreement follows Theragnostics' global licensing agreement for rPARPi with Memorial Sloan Kettering Cancer Center (MSK), USA, a world leading facility in oncology research and cancer treatment in February 2019. Together these agreements give Theragnostics flexibility and expanded capabilities to design and develop a broad range of both diagnostic and therapeutic molecular radiotherapies.
About Theragnostics
Theragnostics is a private clinical-stage pharmaceutical company developing precision oncology products for diagnostic medical imaging and targeted radionuclide therapy. The Company has completed a number of proof-of-concept phase I and II clinical trials for several radionuclide diagnostics and targeted therapies.
About rPARPi
rPARPi was invented and developed within the lab of Thomas Reiner, PhD, at Memorial Sloan Kettering Cancer Center, New York, where the positron emission tomography (PET) agent [18F]PARPi is currently recruiting patients in a Phase I clinical trial in head and neck cancers. The core structure of the developed rPARPi agents allow for their application as theragnostic agents – they can be labelled with diagnostic isotopes as well as with isotopes to enable cancer therapy.
About PARP
Poly (ADP-ribose) polymerase (PARP) enzymes are involved in normal cellular processes including DNA damage response. PARP activity and expression are up-regulated in tumour cells and through the inhibition of PARP it is possible to render cancer cells unable to respond effectively to DNA damage, such as DNA single-strand break. Currently approved PARP inhibitors also actively trap PARP onto DNA resulting in the generation of DNA double-strand breaks that can result in cancer cell death. PARP inhibitors are a rapidly emerging drug class showing promise as anti-cancer agents in a range of tumour types.
Back to HCB News
